A. Oliver Sartor, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Myriad
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Constellation
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Clovis
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Bristol Myers Squibb
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Novartis
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Bavarian Nordic
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Progenics
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Astellas
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Specialty Not Specified)
    Ineligible company:
    Invitae
    Date added:
    Date updated:
    09/19/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Advancel Accelerator Applications (AAA)
    Date added:
    Date updated:
    09/19/2022

Pages

Return to Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment Webcast (2021)